SITC Cancer Immunotherapy Guidelines

“Through initiatives like the SITC Cancer Immunotherapy Guidelines, SITC seeks to provide an important and well documented resource of information to oncologists and other clinical care providers so that they can achieve the best outcomes for their patients,” said SITC President Mario Sznol, MD.

MILWAUKEE (PRWEB)
December 20, 2019

Motivated by the substantial progress in translational and clinical research and improved clinical outcomes seen in recent years, the Society for Immunotherapy of Cancer (SITC) today published updated Cancer Immunotherapy Guidelines for the treatment of patients with advanced renal cell carcinoma.

“The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC),” authored under the guidance of the SITC Cancer Immunotherapy Guidelines Renal Cell Carcinoma Subcommittee, provides oncologists and other advanced practice providers an updated clinical roadmap to treating this disease with immunotherapies approved by the United States Food and Drug Administration (FDA), including the promising class of therapies known as checkpoint inhibitors.

“Immunotherapies using interferon-alpha and interleukin-2 have been the only available options for initial treatment of patients with advanced renal cell carcinoma for the past couple of decades and some patients have benefited tremendously,” said Michael B. Atkins, MD, co-chair of the SITC Cancer Immunotherapy Guidelines Renal Cell Carcinoma Subcommittee. “Now that checkpoint inhibitors are FDA-approved and available for a broad population of patients, our SITC subcommittee developed this manuscript to help provide medical oncologists with expert guidance for incorporating various immunotherapy agents and regimens into their practice.”

The SITC guidelines are comprised of consensus expert recommendations that serve to inform clinicians about all aspects of patient management for advanced renal cell carcinoma during immunotherapy. Updated to reflect the U.S. FDA approval of checkpoint inhibitors as front-line treatments for renal cell carcinoma, the publication includes consensus statements on treatment selection and sequencing, the use of predictive biomarkers and appropriate patient testing, and the management of adverse events. Published in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal, the guidelines are an update to the society’s previously published renal cell carcinoma treatment recommendations from November 2016.

“One of the most important objectives for SITC is to disseminate the latest advances in cancer immunotherapy research,” said SITC President Mario Sznol, MD. “Through initiatives like the SITC Cancer Immunotherapy Guidelines, SITC seeks to provide an important and well documented resource of information to oncologists and other clinical care providers so that they can achieve the best outcomes for their patients.”

The SITC Cancer Immunotherapy Guidelines are a collection of unbiased consensus statements developed by leading experts to help oncologists determine when and how to best use immunotherapy to treat their patients. SITC has published Cancer Immunotherapy Guidelines on cutaneous melanoma, prostate and bladder carcinomas, head and neck squamous cell carcinoma, non-small cell lung cancer and hematologic malignancies. Additional guidelines are in development covering acute leukemia, lymphoma, multiple myeloma and immune-related adverse events.

Join Free Webinar to Learn More about these Guidelines with Leading Experts

Oncologists, nurses and other members of the cancer care team can continue their learning by participating in a free SITC webinar dedicated to discussion of the HNSCC guidelines on Tuesday, Jan. 7, 2020, at 11 a.m. EST. The following experts will present during the free webinar and lead a question-and-answer session with participants: Michael B. Atkins, MD (Georgetown-Lombardi Comprehensive Cancer Center); Dena Battle (KCCure); David McDermott, MD (Beth Israel Deaconess Medical Center); and Brian Rini, MD (Vanderbilt University Medical Center).

This activity is approved for AMA PRA Category 1 Credits™ and is eligible for ACPE and ANCC credit, see registration website for details. The webinar is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer. It is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.

Details of this webinar, including how attendees can register, are available on the SITC website, SITC Cancer Immunotherapy CONNECT.

About SITC

Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

About JITC

Journal for ImmunoTherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of the Society for Immunotherapy of Cancer featuring an impact factor of 8.728. The journal publishes high-quality articles on all aspects of tumor immunology and cancer immunotherapy, on subjects across the basic science-translational-clinical spectrum. JITC publishes original research articles, literature reviews, position papers and practice guidelines, and case reports; invited commentaries may also be commissioned by the journal editors. These articles, freely accessible at jitc.biomedcentral.com, make JITC the leading forum for tumor immunology and cancer immunotherapy research. Follow JITC on Twitter @jitcancer.

# # #

Share article on social media or email:

The Centers for Disease Control (CDC) estimates that influenza claims the lives of between 12,000 and 61,000 annually and a shocking 80,000 in 2017.

NEW YORK (PRWEB)
December 20, 2019

As flu season continues, Mediaplanet today announces the launch of this December’s edition of “Fighting the Flu.” This campaign spotlights the dangers of the influenza virus, which is extremely common and, in some cases, deadly. Healthcare experts and other advocates point to key steps to prevent the flu, especially among children, as well as how to care for those who are ill.

The Centers for Disease Control (CDC) estimates that influenza claims the lives of between 12,000 and 61,000 annually and a shocking 80,000 in 2017. Some experts say an influenza pandemic in the future is possible, which is why researchers are working hard to create new and more effective treatments to fight the illness. In the meantime, experts across the board urge everyone who can get the influenza vaccine, as it is the single best defense there is against the virus. Experts also advise washing hands often and thoroughly with soap and water, disinfecting all surfaces, and avoiding contact with the nose, eyes, and mouth.

The print component of “Fighting the Flu” is distributed within today’s edition of USA Today in Chicago, Los Angeles, Boston, South Florida, New York, and Washington DC/Baltimore markets, with a circulation of approximately 200,000 copies and an estimated readership of 600,000. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: https://www.futureofpersonalhealth.com/campaign/fighting-the-flu/

The family of a young mother who lost her life after a weeks-long battle with an aggressive strain of flu virus, shares her story within the publication, in the hopes their tragedy will encourage others to take important prevention steps. Kendra Mann-O’Brien was a healthy mother of two when she caught the virus, which progressed rapidly and, despite life-saving efforts, eventually claimed her life. Her mother, Joan, is now an outspoken advocate for the flu vaccine, which is the single best way to prevent the spread of the illness and its associated complications.

Online, celebrity doctor, Dr. Oz, shares his best tips for flu prevention and care. In addition to getting the vaccine and regularly washing hands, Dr. Oz advises making healthy choices to strengthen and support the immune system. “Sleeping for seven to nine hours a night is a good way to do this, since sleep is an important regulator of immune function,” he says, continuing, “Eating lots of fruits and vegetables and other foods rich in vitamin C, vitamin B6, and vitamin E will also help your immune system.”

This campaign was made possible with the support of the Center for Disease Control and Prevention (CDC), Families Fighting Flu, National Foundation for Infectious Diseases, American Hospital Association, American Heart Association, American Red Cross, Healthline, Commonwealth Care Alliance, National PTA, American Lung Association, American Academy of Pediatrics, HealthyChildren.org, Consumer Healthcare Products Association, American Pharmacists Association, Medical News Today, Prevention.com, Dr. Oz, Luden’s, Chloraseptic, CleanWell, Nissin Foods, Carmex, and Dollar Tree.

About Mediaplanet

Mediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do.

Press Contact:

Kevin Duke

kevin.duke@mediaplanet.com

(646) 755-7950

Share article on social media or email:

“This designation recognizes Dr. Adam Shrewsberry as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
December 20, 2019

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Adam Shrewsberry M.D., Tennessee Urology in Oak Ridge, TN, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Shrewsberry has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Adam Shrewsberry as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Mercy College

DOBBS FERRY, N.Y. (PRWEB)
December 20, 2019

Mercy College is pleased to announce the official approval of the New York State Education Department to expand the College’s nursing programs to provide increased degree offerings online and at the Dobbs Ferry, MercyManhattan and Bronx Campuses. The new degree programs, part of the College’s School of Health and Natural Sciences, were added to help alleviate the nursing shortage in the Tri-State area and across the nation. The expanded programs also provided a seamless pathway for students to continue their education after the former College of New Rochelle (CNR) ceased academic operations in August 2019.

“Mercy College has established a comprehensive nursing program under the guidance of Dr. Deborah Hunt and Dr. Miriam Ford that will provide current and prospective nurses with numerous educational opportunities,” said Joan Toglia, Dean of the School of Health and Natural Sciences. “Mercy bridges the gap between what nursing students learn in a classroom setting and real-life experiences in a health care setting – resulting in sought after job placements of our graduates.”

“Having a quality academic institution like Mercy College anticipate and respond to the needs of the market helps provide economic value to the entire Tri-State region,” said William M. Mooney, Jr., President and CEO of The Westchester County Association. “We are looking forward to working with the College as it helps to fill the region’s nursing shortage.”

Mercy’s four-year traditional nursing program, which launched in 2015 and has been at capacity since its inception, has now tripled in size. The first cohort of 23 students were recognized at a pinning ceremony in May 2019 and on December 20, 2019, the first cohort of 106 teach-out students from the former CNR will celebrate their pinning ceremony.

“There’s great demand for highly trained nurses,” explained Deborah Hunt ‘86, Ph.D., R.N., Professor and Executive Director of Nursing Special Programs, and former Interim Dean of CNR’s School of Nursing and Health Professions. “Mercy is providing nursing programs at the undergraduate and graduate levels as patient demands become more complex and the aging population requires increased levels of care and nurses who practice from a holistic perspective who are able to think critically, utilize current evidence, and promote positive patient outcomes.”

Based on unemployment projections by The Bureau of Labor Statistics, there is an estimated need for more than 200,000 new registered nurses each year through 2026 to help fill jobs vacated by retirees. Mercy is working to combat this decline by increasing the nursing talent in our communities through in-demand undergraduate and graduate degree programs. Undergraduate programs include the Accelerated Second Degree in Nursing, Traditional Nursing (four-year program) and the R.N. to B.S. program. The College also offers opportunities for nurses to earn their master’s degrees in three areas, including Family Nurse Practitioner, Nursing Administration and Nursing Education. The College is planning to offer additional nursing programs in the future and has applied for approval to teach Traditional Nursing in the Bronx.

“It is important to tailor courses for busy nurse professionals,” said Miriam Ford, Ph.D, FNP-BC, Chief Nurse Administrator and Director of Dobbs Ferry and MercyManhattan. “These new program offerings at multiple locations will ensure student success by providing individualized attention, convenient scheduling and small class sizes.”

In addition to new course offerings, the College has created state-of-the-art classrooms that replicate real-world clinical lab and hospital environments. They include the Health Professions Clinical Simulation Lab, Hospital Simulation Lab and a cutting-edge 12,000 square foot space that includes specialized labs designed to simulate different disciplines within a health care facility. In addition, nursing students have access to the Health Assessment Lab which allows them to learn to conduct health assessments in a setting supplied with equipment typically seen in hospitals and clinics.

For additional information on these programs and locations please contact Miriam Ford mford@mercy.edu or 914-674-7865.

About Mercy College

Founded in 1950 by the Sisters of Mercy, Mercy College is an independent, coeducational college that offers more than 90 undergraduate and graduate degree and certificate programs within five schools: Business, Education, Health and Natural Sciences, Liberal Arts and Social and Behavioral Sciences. The vibrancy of the College culture is sustained by a diverse student body from around the region. The College offers campuses in Dobbs Ferry, Bronx, Manhattan and Yorktown Heights with additional teaching locations in New Rochelle, Brooklyn and Harlem as well as online offerings.

About the Mercy College Nursing Program

Mercy College offers nursing programs tailored for busy nurse professionals with individualized attention, convenient scheduling and small classes. The following programs are available at these locations. Bronx Campus: Accelerated Second Degree in Nursing, B.S. MercyManhattan: Nursing Education, M.S., Nursing Administration, M.S. Dobbs Ferry: Nursing (Traditional Program) B.S., Nursing (RN to B.S.), B.S., Nursing Administration, M.S., Nursing Education, M.S. Online: Nursing (RN to B.S.), B.S., Nursing Education, M.S., Nursing Administration, M.S

The College is planning to offer additional nursing programs in the future and has applied for approval to teach Traditional Nursing in the Bronx.

Share article on social media or email:

“We are proud to name Dr. Christopher Pieczonka as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
December 20, 2019

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Christopher M. Pieczonka, M.D., Associated Medical Professionals in Syracuse, NY, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Pieczonka has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Christopher Pieczonka as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Dr. Cherag Daruwala

Like many gastroenterologists, I enjoy the technological aspect of my specialty. Because of my training and experience, I am proud to have been the first gastroenterologist in Central New Jersey to offer endoscopic ultrasound.

SCOTCH PLAINS, N.J. (PRWEB)
December 19, 2019

NJ Top Docs has reviewed and approved Dr. Cherag Daruwala of Hunterdon Gastroenterology Associates for 2019. This is the fourth consecutive year Dr. Daruwala has been reviewed and approved. He is board certified in Gastroenterology and Hepatology.

After completing his gastroenterology fellowship, Dr. Daruwala went on to complete training in endoscopic ultrasound and was on staff at Temple University Hospital for 3 years prior to joining Hunterdon Gastroenterology. Dr. Daruwala established the endoscopic ultrasound program at Hunterdon Medical Center.

“Like many gastroenterologists, I enjoy the technological aspect of my specialty. Because of my training and experience, I am proud to have been the first gastroenterologist in Central New Jersey to offer endoscopic ultrasound. This emerging technology is quickly becoming the gold standard in the diagnosis of various gastrointestinal illnesses. With endoscopic ultrasound, we are able to get high quality information about a patient’s condition in a way that is much easier and less invasive than other diagnostic procedures,” says Dr. Daruwala.

He adds, “Hunterdon Gastroenterology Associates is very technology-forward, investing in new and proven diagnostic and treatment equipment and systems that make a difference in the comfort, convenience and outcomes of our procedures. This is an important reason we are leaders in the region when it comes to gastroenterology—and one of many reasons I am enjoying being the newest member of the team.”

To learn more about this NJ Top Doc, please click here: https://njtopdocs.com/nj-doctors/daruwala/

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook and Twitter

Share article on social media or email:

Marin County Dental Implants

San Francisco is a high-energy city to work and play. When it comes to daily life, some folks prefer a slower pace.

SAN FRANCISCO (PRWEB)
December 20, 2019

San Francisco Dental Implant Center, a best-in-class clinic for quality dental implants in San Francisco but serving Marin County residents as well, is proud to announce a new post on 2020 preparations. The post explains that residents of Marin County who are looking to self-improvement for 2020 might consider a short commute into San Francisco for dental implants. The post explains that if a short drive is worth it for a better dinner, it is certainly worth it for a better-looking smile in 2020.

“San Francisco is a high-energy city to work and play. When it comes to daily life, some folks prefer a slower pace. Many areas around the city, including Marin, offer the perfect balance for locals,” explained Dr. Alex Rabinovich, chief oral surgeon of San Francisco Dental Implants. “Marin County residents can enjoy a quieter daily existence, yet easily access world-class services nearby. A short commute can bring them right to our door for professional dental implant surgery.”

Residents of Marin County and the surrounding Bay Area can review the new post from San Francisco Dental Implant Center at https://www.sfdentalimplants.com/blog/marin2020/. Oral procedures, including dental implants, tooth replacement, jaw surgery, or wisdom tooth removal, are easy to schedule and drive to from the Bay Area suburbs. Indeed, Marin County residents can review the newly updated Marin-specific informational page at https://www.sfdentalimplants.com/SFDIC-address-marin/.

MARIN COUNTY RESIDENTS FIND THE BEST DENTAL IMPLANTS ARE RIGHT OVER A BRIDGE IN SAN FRANCISCO

Here is the background for this release. Several areas surrounding the bustling city of San Francisco can offer a quieter option for slower-paced individuals. Many residents of nearby suburbs might commute to The City for work, dining, and entertainment. A medical community offering the best in cutting-edge treatments and surgery are also prevalent in The City by the Bay. Locals living in Marin County ready to learn about dental implants can find the best NorCal dental implant clinic right next door in ‘The Big City.’

Leading-edge procedures include; trefoil dental implants, teeth-in-a-day, and all-on-four. Innovative pain management protocols and an attentive clinic team could help patients recover quickly. For these reasons, SF Dental Implants is proud to announce a new post about the advantages of living near a premier city.

ABOUT SAN FRANCISCO DENTAL IMPLANT CENTER

San Francisco Dental Implant Center, under the direction of Dr. Alex Rabinovich, focuses on the placement and restoration of dental implants, making it among the top-rated dental implant clinics in the San Francisco Bay Area. Dr. Rabinovich is a Board Certified Oral and Maxillofacial Surgeon specializing in the field of dental implants. This additional training, along with his years of experience, sets Alex Rabinovich MD DDS apart from the growing number of general dentists offering dental implant treatments. The cost of dental implants in the Bay Area can be easy to manage with payment plans available. San Francisco Dental Implant Center serves the San Francisco Bay Area, including Marin County areas such as Tiburon, Sausalito, and Mill Valley.

Contact:

San Francisco Dental Implant Center, Media Relations

Web. http://www.sfdentalimplants.com/

Email. visage.sanfran@gmail.com

Share article on social media or email:

MONROVIA, Calif. (PRWEB)
December 19, 2019

Stayhealthy’s popular Color Quest AR app, which is dedicated to educating and engaging children about their health using augmented reality, coloring, and health facts, has just passed the one million download mark. The Snack Town All-Stars, a band made up of characters from the world of Color Quest, has hit the charts at number 5 on Apple Music’s Children’s Christmas Playlist with their latest release, “The Healthy Holiday Mashup”.

“We’re thrilled to see the All Stars rising to become a leader in children’s music and entertainment,” stated Paul Ring, President of Stayhealthy Music and Entertainment. “Being recognized by Apple Music and added to their Christmas Children’s Playlist is very rewarding when we’re in the classic company of Raffi, Baby Shark, Alvin and the Chipmunks, Frozen, and White Christmas. The best part of all is knowing that kids will be celebrating the holidays by staying active and singing along with songs about healthy foods.”

“It’s been great to see how the Color Quest brand and the Snack Town All-Stars character set are growing. It’s amazing enough that the Color Quest YouTube video has over 29 million views, but we’re especially proud that the app has received 5 star reviews from Apple’s Educational App Store and has been the number one trending education app in Google Play,” said John Collins, Stayhealthy’s CEO. “Now with the app passing one million downloads, it really sends the message that parents and children are welcoming the opportunity to learn about health and nutrition at the same time they’re having fun.”

The Snack Town All-Stars’ new release, “The Healthy Holiday Mashup”, features a medley of the most popular holiday songs with fun messaging about health throughout. The track is the latest in Stayhealthy Music and Entertainment’s music and dance videos for children that combine active engagement and education about healthy lifestyles. The band’s first release, “The Stayhealthy Shake”, which has over 700,000 views on YouTube (and with the Holiday Mashup now has over 100,000 streams), was developed to meet the company’s ongoing mission of encouraging children to be more active.

Stayhealthy Music and Entertainment was founded by Stayhealthy, Inc., a company dedicated to innovating new ways of engaging, educating and empowering people about their personal health and wellness. The new company has recently signed with Universal Music Group on worldwide distribution for its children’s music.

Please Visit https://snacktownallstars.com/

For more information: colorquestar.com

About Stayhealthy, Inc.

Founded in 1995, Stayhealthy Inc. is a healthcare technology company that has brought together the most advanced tools to measure, track, and change the health and wellness status of millions of users. Over the decades, Stayhealthy has learned what doesn’t work in healthcare, and as a result, has identified engagement, education and retention as its core strategic initiatives. Stayhealthy is now launching a mobile platform with apps based on highly accurate, clinically valid screening tools delivered with patented augmented reality technology.

Led by Chairman and former Secretary of Health and Human Services, Governor Tommy Thompson, Stayhealthy’s mission has been focused on successfully addressing the growing epidemic of diseases that are linked directly to excess body fat such as many cancers, Type 2 diabetes, heart disease, and stroke.

Share article on social media or email: